Latest studies
- RecruitingPhase III
Phase 3, randomised, double-blind, placebo- controlled, 3-arm study to investigate the safety and efficacy of efimosfermin alfa in participants with biopsy-confirmed F2- or F3-stage metabolic dysfunction-associated steatohepatitis (MASH) (ZENITH-1)
This clinical trial is testing a new injection called efimosfermin alfa for people with metabolic dysfunction-associated steatohepatitis (MASH), an inflamed fatty liver condition. Researchers want to see if monthly injections over four years can safely reduce liver fat, ease inflammation, and improve liver scarring compared to a dummy treatment.
Medical condition: Metabolic Dysfunction-Associated Steatohepatitis (MASH) Medical condition in lay language: Metabolic Fatty Liver Inflamation Therapeutic areas: Diseases [C] - Nutritional and Metabolic Diseases [C18]Hong Kong - RecruitingPHASE1, PHASE2
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
This study is looking at a new drug called repotrectinib for advanced cancers that have specific gene changes (ALK, ROS1, or NTRK). It aims to find the best dose and see how well it works in shrinking tumours and how safe it is.
Locally Advanced Solid TumorsMetastatic Solid TumorsHong Kong - Recruiting
Pompe Disease Registry Protocol
This registry tracks people with Pompe disease globally. It helps us understand the condition better, how it changes over time, and the effects of treatments. The goal is to improve care for everyone with Pompe disease.
Glycogen Storage Disease Type IIPompe DiseaseHong Kong - Active not recruitingPHASE2
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
This study is looking at new ways to treat advanced liver and bile duct cancers. It tests new medicines, called immunomodulators, either on their own or alongside other cancer drugs, to see how well they work and if they are safe.
Hepatocellular CarcinomaBiliary Tract CancerHong Kong - RecruitingPHASE3
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
This study compares a new medicine called nemtabrutinib with existing treatments (ibrutinib or acalabrutinib) for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who haven't had treatment before. The aim is to see if the new drug is as good or better.
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaHong Kong - RecruitingPHASE3
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
This study looks at a new drug, Surovatamig, combined with rituximab, for people with previously untreated follicular lymphoma. It compares this new combination therapy with standard treatments to see if it works better and is safe.
Untreated Follicular LymphomaHong Kong - Active not recruitingPHASE3
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This study looks at new treatments for a type of lung cancer where standard treatment has stopped working. It compares a drug called Dato-DXd, alone or with osimertinib, against usual chemotherapy to see which helps patients live longer without their cancer getting worse.
Metastatic Non-small Cell Lung CancerHong Kong - Active not recruitingPHASE3
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
This study is looking at a new medicine called ravulizumab for adults with a kidney condition called IgAN. We want to see if it helps reduce kidney damage and improve kidney function compared to a dummy medicine.
Immunoglobulin A NephropathyIgANHong Kong - Active not recruitingPHASE3
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
This study looks at a new drug, trastuzumab deruxtecan, for people in the UK with HER2-positive stomach or food pipe cancer. It compares this drug to standard treatments for patients whose cancer has grown despite previous therapy. The aim is to see if the new drug works better and is safe.
Gastric Cancer, AdenocarcinomaGastroesophageal Junction AdenocarcinomaHong Kong - RecruitingPHASE2, PHASE3
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
This study looks at a new drug, Navlimetostat, combined with standard treatments for advanced lung cancer. It compares this combination to standard treatments alone in patients whose cancer has a specific genetic change called an MTAP deletion. The aim is to see if the new combination works better.
Metastatic Non-small Cell Lung Cancer With MTAP DeletionHong Kong - RecruitingPHASE2
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
This study is testing a new medicine, ADX-038, for adults with certain kidney diseases caused by a problem with the body's immune system, called the complement system. We want to see if it's safe and helps people with conditions like IgA nephropathy (IgAN) or C3 glomerulopathy (C3G).
IgANC3GComplement-mediated Kidney DiseaseIgA Nephropathy (IgAN)Hong Kong - Active not recruitingPHASE4
RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)
This study compares two treatments, Radium-223 (Xofigo) and ARPI therapy, for prostate cancer that has spread to the bones. It aims to see which is more effective and safer for men who have already tried ARPIs.
Metastatic Castrate Resistant Prostate Cancer (mCRPC)Hong Kong - Recruiting
Fabry Disease Registry & Pregnancy Sub-registry
This study tracks the health of people with Fabry disease over time, including pregnant women. It helps doctors better understand the disease and improve care, without giving any new treatments. It's about observing, not experimenting.
Fabry DiseaseHong Kong - Active not recruitingPHASE3
Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)
This study is looking at two new drugs, durvalumab and tremelimumab, for advanced lung cancer. It compares them to standard chemotherapy. Researchers want to see if the new combination helps people live longer and is safe as a first treatment for this type of cancer.
Non Small Cell Lung Carcinoma NSCLCHong Kong - Active not recruitingPHASE3
Atrasentan in Patients With IgA Nephropathy
This study is testing a new medicine, atrasentan, for people with a kidney disease called IgA nephropathy. It compares atrasentan to a dummy pill (placebo) to see if it can slow down kidney damage and improve kidney function.
IgA NephropathyImmunoglobulin A NephropathyHong Kong - RecruitingPHASE3
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
This study is looking at a new combination of medicines for a type of lung cancer that has spread or can’t be removed by surgery. It compares a drug called trastuzumab deruxtecan plus pembrolizumab to standard chemotherapy plus pembrolizumab.
Non-small Cell Lung CancerHong Kong - Active not recruitingPHASE2
A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)
This study is testing new medicines, daplusiran/tomligisiran (DAP/TOM) and bepirovirsen, for people with long-term Hepatitis B. It aims to find the best dose of DAP/TOM to use with bepirovirsen to improve treatment.
Chronic Hepatitis B Virus InfectionHepatitis BHong Kong - RecruitingPHASE3
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
This study is testing new combinations of medicines for advanced liver cancer (hepatocellular carcinoma) that can't be cured with surgery. It compares different drug blends to a common treatment to see which works best and is safest.
Hepatocellular CarcinomaHong Kong - RecruitingPHASE3
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
This study is looking at two different treatments, pumitamig and durvalumab, for people with a type of lung cancer called non-small cell lung cancer (NSCLC) that can't be removed by surgery. It's for patients who have already had chemotherapy and radiation.
Non-small Cell Lung Cancer (NSCLC)Hong Kong - RecruitingPHASE3
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
This study is for adults with a certain type of lung cancer (Stage II-IIIB non-small cell lung cancer) that has a specific genetic change (HER2 mutation) and has been fully removed by surgery. It compares a new daily tablet called zongertinib with standard treatments to see if it can stop the cancer from coming back.
Non-small Cell Lung CancerHong Kong - Active not recruitingPHASE3
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
This study compares a new medicine, Sacituzumab Tirumotecan, with standard chemotherapy for advanced lung cancer. It’s for people whose cancer has specific genetic changes and has already been treated. We're looking to see if the new medicine helps people live longer and keeps their cancer from growing for longer.
Non-small Cell Lung Cancer (NSCLC)Hong Kong - RecruitingPHASE3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
This study looks at the long-term safety and effectiveness of a cancer drug called pembrolizumab (and related treatments) for people with advanced cancers. It's for patients who are already receiving these treatments in other studies and want to continue.
Solid TumorsHematologic MalignanciesHong Kong - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
This study is testing a new medication called Tulisokibart for people with moderate to severe Crohn's disease. Researchers want to see if it's safe and effective in reducing symptoms and improving the gut lining. It involves different ways of giving the medicine compared to a dummy treatment.
Crohn's DiseaseHong Kong - Active not recruitingPHASE3
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
This study is testing a new drug, AZD0901, for advanced stomach cancer or where the food pipe meets the stomach. It's for people whose cancer has Claudin18.2 protein and has already been treated before. Researchers want to see if AZD0901 works better and is safer than other treatments.
Gastric CancerGastroesophageal Junction CancerHong Kong - RecruitingPHASE2
Pan Tumor Rollover Study
This study looks at the long-term safety of different cancer treatments, including nivolumab, alone or combined with other medicines. It's for people with various types of cancer who are already receiving treatment in a related study, aiming to see how these treatments work over time.
CancerHong Kong - RecruitingPHASE3
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
This study is testing a new drug, daraxonrasib, for people with a specific type of advanced lung cancer (non-small cell lung cancer, or NSCLC) that has a RAS gene change. It compares the new drug to an existing chemotherapy, docetaxel, to see if it works better or has fewer side effects.
NSCLC (Non-small Cell Lung Cancer)Non-Small Cell Lung CancerNSCLCNSCLC (Non-small Cell Lung Carcinoma)Hong Kong - Active not recruitingPHASE3
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
This study is looking into a new combination of medicines for people in the UK with multiple myeloma that has come back or not responded to previous treatments. It compares a new medicine combination with a standard one to see if the new option works better.
Relapsed or Refractory Multiple MyelomaHong Kong - RecruitingPHASE3
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
This study is looking into a new medicine called Seladelpar for people with a liver condition called Primary Biliary Cholangitis (PBC) and mild liver scarring (cirrhosis). It aims to see how well Seladelpar works compared to a dummy pill to improve health outcomes.
Primary Biliary CholangitisHong Kong - Active not recruitingPHASE3
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
This study is looking at a new drug, quizartinib, combined with standard chemotherapy for adults recently diagnosed with a specific type of leukaemia called AML. We want to see if this combination improves treatment outcomes compared to chemotherapy alone.
LeukemiaHong Kong - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
This study is looking at a new medicine called icotrokinra for people with psoriatic arthritis. We want to see if it helps reduce joint pain and swelling, and if it's safe. Some people will get the new medicine, others a dummy medicine.
Arthritis, PsoriaticHong Kong - Active not recruitingPHASE3
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
This study looks at a new drug, patritumab deruxtecan, for a type of lung cancer that has stopped responding to standard treatments. It compares this new drug with traditional chemotherapy to see if it works better and is safer for patients.
Nonsquamous Non-small Cell Lung CancerEGFR L858REGFR Exon 19 DeletionHong Kong - Active not recruitingPHASE3
A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults
This study is looking at a specific shingles vaccine in older adults. It wants to see how well the vaccine continues to protect against shingles for many years, how strong the body's immune response remains, and if it's still safe over a long time.
Herpes ZosterHong Kong - Active not recruitingPHASE3
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
This study compares a new drug, TAK-788, with standard chemotherapy for advanced lung cancer (NSCLC) where the cancer has a specific genetic change (EGFR exon 20 insertion mutation). It's for people who haven't had prior treatment for their advanced cancer.
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)Hong Kong - RecruitingPHASE3
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
This study looks at new treatments for a type of blood cancer called Acute Myeloid Leukemia (AML) in people who are newly diagnosed. It's comparing a new drug, bleximenib, with existing treatments (Venetoclax and Azacitidine) and a dummy drug (placebo) to see how well they work.
Leukemia, Myeloid, AcuteHong Kong - Active not recruitingPHASE2
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
This study is for people with cancer that has spread, who are already benefiting from a specific medicine called trastuzumab emtansine (T-DM1) or other similar treatments in an earlier study. It allows them to keep receiving these important treatments for longer to see if they continue to help.
Neoplasm MetastasisHong Kong - Active not recruitingPHASE3
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
This study looks at a new drug, imlunestrant, for early breast cancer. It compares it to standard hormone treatments like tamoxifen, anastrozole, letrozole, and exemestane. The goal is to see if imlunestrant works better for patients whose cancer is at higher risk of returning.
Breast NeoplasmsHong Kong - Recruiting
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
This study looks at how well Medtronic heart devices, like pacemakers and defibrillators, perform over a long time. It helps ensure these devices are reliable and safe for people with heart conditions such as irregular heartbeats or heart failure.
ArrhythmiaBradycardiaHeart FailureSinus TachycardiaHong Kong - Active not recruitingPHASE1
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
This study tests a new medicine called zongertinib for advanced cancers with changes in the HER2 gene. It aims to find the right dose and see if it can shrink tumours, especially in non-small cell lung cancer.
Neoplasm MetastasisNon-Small Cell Lung CancerHong Kong - RecruitingPHASE3
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
This study is looking at a new treatment called AAA817, combined with standard prostate cancer drugs, for men with advanced prostate cancer. It compares this new combination to existing treatments to see which works best at slowing the cancer's growth.
Prostate CancerHong Kong - Active not recruitingPHASE1
A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)
This study looks at new drug combinations for treating advanced stomach, bile duct, and pancreatic cancers. It focuses on cancers with a specific genetic change (MTAP-deletion) to see how safe and effective these new treatments are.
Advanced Gastrointestinal, Biliary Tract, and Pancreatic CancersHong Kong - Active not recruitingPHASE3
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
This study looks at new drug combinations for bladder cancer that has spread into the muscle. It compares them to standard treatment for people who can't take or don't want cisplatin chemotherapy before surgery to remove their bladder. The aim is to find more effective and safe options.
Muscle Invasive Bladder CancerHong Kong - Active not recruitingPHASE3
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
This study looks at new treatments (Durvalumab and Domvanalimab) for advanced lung cancer (Stage III NSCLC) after standard radiation and chemotherapy. It aims to see if combining these medicines helps patients whose cancer hasn't worsened after initial treatment.
Non-Small Cell Lung CancerHong Kong - Active not recruitingPHASE3
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
This study looks at new drug combinations for advanced lung cancer. It compares a new drug (Datopotamab Deruxtecan) with an existing treatment (Pembrolizumab) and chemotherapy, to see if the new combinations are safer and work better.
Metastatic Non Small Cell Lung CancerHong Kong - Active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
This study is testing a new combination of medicines, Giredestrant and Palbociclib, for advanced breast cancer. It's for people whose cancer is hormone-sensitive (ER-positive) but not HER2-positive. Researchers want to see if this new combination works better and is safer than a standard treatment.
Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast CancerHong Kong - RecruitingPHASE3
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
This study is testing new ways to treat advanced bowel cancer (colorectal cancer) that has spread to other parts of the body. It compares a new drug, Precem-TcT, alone or with another treatment called bevacizumab, against a standard treatment, to see which works best.
Metastatic Colorectal CancerHong Kong - RecruitingPHASE3
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
This study looks at a new medicine called Tozorakimab. We want to see if it can help people in hospital with lung infections who need extra oxygen. The goal is to stop them from getting sicker, like needing a breathing machine, or even dying.
Viral Lung Infection and Acute Respiratory FailureHong Kong - Active not recruitingPHASE2
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
This study looks at a drug called entrectinib for different types of advanced cancer. It focuses on cancers with specific genetic changes (NTRK, ROS1, or ALK gene fusions). Researchers want to see if entrectinib can help treat these cancers.
Breast CancerCholangiocarcinomaColorectal CancerHead and Neck NeoplasmsHong Kong - Active not recruitingPHASE3
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
This study looks at a new medicine called risankizumab for Crohn's disease. We're checking how well it works and if it's safe for people who have already started treatment. It's like a follow-up to see how different doses work and how people feel over time.
Crohn's DiseaseHong Kong - Active not recruitingPHASE3
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
This study looks at a new medicine, pelacarsen, for people with heart and circulation problems and high levels of a specific fat called Lp(a). It aims to see if it's safe and effective when used alongside another medicine, inclisiran.
Atherosclerotic Cardiovascular Disease (ASCVD)Hong Kong - Active not recruitingPHASE2
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
This study is for people with advanced solid cancers that haven't responded to other treatments. It uses a "precision medicine" approach, matching treatments to the specific genetic changes found in each person's tumour, aiming for more effective and personalised care.
Solid TumorsHong Kong